Bgt Biogenomic Technology Italia S.p.A. bgtitalia.it


La BGT Italia u00e8 una societu00e0 di biotecnologie che si pone come soggetto imprenditoriale per lo sviluppo economico di importanti filoni di ricerca nel settore della genetica, associando nella propria compagine societaria sia competenze di tipo gestionale e manageriale, sia competenze tecnico-scientifiche di rilevante importanza e notorietu00e0. Il soggetto imprenditoriale nato nel 2002 promuove e sostiene attivitu00e0 di ricerca industriale e sviluppo pre-competitivo con alto potenziale di...Show all

La BGT Italia u00e8 una societu00e0 di biotecnologie che si pone come soggetto imprenditoriale per lo sviluppo economico di importanti filoni di ricerca nel settore della genetica, associando nella propria compagine societaria sia competenze di tipo ...Show all

Company (Alive / Active)

Phone:

Fax:

Z.I. "La Marinella"
07046
Italy

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Bgt Biogenomic Technology Italia S.p.A. $0M Mar 19, 2019
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Bgt Biogenomic Technology Italia S.p.A. Jobs

jobs by Indeed job
						search
There is no Investors data available for this company. Please select another tab.
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Sanomune

Winnipeg, Manitoba, Canada
Alive / ActiveSanomune is a private biotech start-up focused on neurological and autoimmune diseases. The company's technology is based on the repurposing of a safe, oral biological to treat large market indications. Sanomune's lead product, SAN-61, is a potential first-in-class treatment targeting the dual hallmark pathologies of Alzheimer's (AD): amyloid beta plaque deposition and the formation of neurofibrillary tangles. No other known therapy can effectively target both aspects of the disease. Sanomune's ...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)